# US 2026/0092271 A1 · Methods and compositions to control gene using genome editing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092271 A1
- Document ID: US20260092271A1
- Status: Published application
- Kind: A1
- Application number: 19/112,198
- Filed: 2023-09-20
- Published: 2026-04-02
- Earliest claimed: 2022-09-20
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Jesse Engreitz; Gabriella Martyn; Michael Montgomery; Benjamin Doughty; Harold Jones; Katherine Guo
- Web page: https://patentgrep.com/patent/US20260092271A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- G16B 20/50: Mutagenesis
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods for screening edited genomic sequences for their effect on expression of a target gene, and for designing a target sequence edit for introducing to a target sequence of a nucleic acid molecule. Also provided are compositions and cells including the edited sequences, and methods for their use in preventing or treating a disease.

## Claims

### Claim 1

A method of screening edited genomic sequences for their effect on expression of a target gene, the method comprising:
providing a population of cells, the genomes of the population of cells comprising a target sequence;
introducing a plurality of different target sequence edits into the genomes of the population of cells;
measuring a parameter for each cell of the population of cells, the parameter correlating with an expression level of the target gene;
separating the population of cells into a plurality of sets based on the measured parameter;
for each combination of (a) a set of the plurality of sets and (b) a target sequence edit of the plurality of different target sequence edits, determining a count of the target sequence edit incorporated into the genomes of the cells of the population of cells in the set; and
for each target sequence edit of the plurality of different target sequence edits, based on the counts in the plurality of sets, computing an effect of the target sequence edit on the expression level of the target gene.

### Claim 2 (depends on 1)

The method of claim 1, wherein the plurality of different target sequence edits comprises a designed target sequence edit identified by a simulation process, the simulation process comprising:
receiving an initial target sequence edit and an initial edit site of the target sequence;
generating an initial edited sequence comprising the target sequence into which the initial target sequence edit is introduced at the initial edit site;
determining an initial predicted level of a molecular feature of a target gene in response to the initial edited sequence;
setting (i) an input target sequence edit equal to the initial target sequence edit, (ii) an input edit site equal to the initial edit site, and (iii) an input level equal to the initial predicted level of the molecular feature;
performing a series of operations in an iterative manner for a plurality of iterations, the series of operations comprising:
(a) generating a test target sequence edit and a test edit site, wherein either:
(i) the test edit site is equal to the input edit site, and the test target sequence edit is a variant of the input target sequence edit; or
(ii) the test target sequence edit is equal to the input target sequence edit, and the test edit site is one position removed from the input edit site in the target sequence;
(b) generating a test edited sequence comprising the target sequence into which the test target sequence edit is introduced at the test edit site;
(c) determining a test predicted level of the molecular feature of the target gene in response to the test edited sequence;
(d) comparing the test predicted level and the input level;
(e) based on the comparing, either
(i) updating (1) the input level to equal the test predicted level, (2) the input target sequence edit to equal the test target sequence edit, and (3) the input edit site to equal the test edit site; or
(ii) leaving the input expression level, the input target sequence edit, and the input edit site unchanged; and
subsequent to the plurality of iterations, reporting the input target sequence edit as the designed target sequence edit.

### Claim 3 (depends on 2)

The method of claim 2, wherein operation (a) of the series of operations comprises
(a) generating a test target sequence edit and a test edit site, wherein either:
(i) the test edit site is equal to the input edit site; and the test target sequence edit is equal to (1) the input target sequence edit from which one nucleotide is deleted, (2) the input target sequence edit in which one nucleotide is substituted, or (3) the input target sequence edit into which one nucleotide is inserted; or
(ii) the test target sequence edit is equal to the input target sequence edit, and the test edit site is one position removed from the input edit site in the target sequence.

### Claim 4 (depends on 3)

The method of claim 3, wherein:
the initial target sequence edit has a length no greater than a threshold length; and
operation (a) of the series of operations comprises
(a) generating a test target sequence edit and a test edit site, wherein either:
(i) the test edit site is equal to the input edit site; and the test target sequence edit is equal to (1) the input target sequence edit from which one nucleotide is deleted, (2) the input target sequence edit in which one nucleotide is substituted, or, if the input target sequence edit has a length at least one bp shorter than the threshold length, (3) the input target sequence edit into which one nucleotide is inserted; or
(ii) the test target sequence edit is equal to the input target sequence edit, and the test edit site is one position removed from the input target sequence edit in the target sequence.

### Claim 5 (depends on 4)

The method of claim 4, wherein the threshold length is no greater than 35 bp.

### Claim 6 (depends on 2)

The method of claim 2, wherein the designed target sequence edit is an insertion sequence.

### Claim 7 (depends on 2)

The method of claim 2, wherein the molecular feature of the target gene comprises a gene expression level, a binding of a transcription factor, an epigenetic mark, or an accessibility to a chromatin.

### Claim 8 (depends on 7)

The method of claim 7, wherein the molecular feature of the target gene is an expression level of the target gene operably linked to the target sequence.

### Claim 9 (depends on 7)

The method of claim 7, wherein the determining of the initial predicted level and the test predicted level comprises use of Cap Analysis of Gene Expression (CAGE).

### Claim 10 (depends on 2)

The method of claim 2, wherein the receiving of the initial target sequence edit comprising randomly generating the initial target sequence edit.

### Claim 11 (depends on 2)

The method of claim 2, wherein the plurality of iterations consists of at least 10 iterations.

### Claim 12 (depends on 2)

The method of claim 2, wherein the method further comprises performing the simulation process, thereby identifying the designed target sequence edit.

### Claim 13 (depends on 1)

The method of claim 1, wherein:
the population of cells contains a fusion protein, the fusion protein comprising a polymerase and a DNA targeting protein, the DNA targeting protein having a nickase activity and binding to the target sequence;
the introducing of the plurality of different target sequence edits comprises introducing to the population of cells a plurality of template polynucleotides, the template polynucleotides each independently comprising a target sequence edit of the plurality of different target sequence edits; and
in at least a portion of the population of cells, a template polynucleotide of the plurality of template polynucleotides is primed by a target sequence nicked by the DNA targeting protein, and copied into the genome by the polymerase.

### Claim 14 (depends on 13)

The method of claim 13, wherein a plurality of prime-editing guide RNA (pegRNA) molecules comprises the plurality of template polynucleotides.

### Claim 15 (depends on 14)

The method of claim 14, wherein the plurality of pegRNA molecules further comprises a gRNA spacer no more than 50 bp away from the target sequence edit.

### Claim 16 (depends on 14)

The method of claim 14, wherein the plurality of pegRNA molecules further comprises a scaffold sequence having at least 85% sequence identity with the sequence:
GTTTAAGAGCTATGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTC
CGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGC.

### Claim 17 (depends on 14)

The method of claim 14, wherein the plurality of pegRNA molecules further comprises a primer-binding site (PBS) having a length between 6 bp and 16 bp.

### Claim 18 (depends on 14)

The method of claim 14, wherein the plurality of pegRNA molecules further comprises a reverse transcription (RT) template having a length no greater than 60 bp.

### Claim 19 (depends on 18)

The method of claim 18, wherein the reverse transcription (RT) template extends between 6 bp and 16 bp upstream of the target sequence edit.

### Claim 20 (depends on 14)

The method of claim 14, wherein the plurality of pegRNA molecules further comprises a 3′ end modification having at least 86% sequence identity with the 37-bp trimmed evopreRQ (tevopreQ1) pseudoknot sequence.

### Claim 21 (depends on 13)

The method of claim 13, wherein the introducing of the plurality of template polynucleotides comprises use of a lentivirus, a transposase, or a recombinase.

### Claim 22 (depends on 21)

The method of claim 21, wherein the introducing of the plurality of template polynucleotides comprises transducing the population of cells with lentivirus.

### Claim 23 (depends on 13)

The method of claim 13, wherein the method further comprises introducing to the population of cells an inducer of expression of the fusion protein.

### Claim 24 (depends on 23)

The method of claim 23, wherein the population of cells comprises cells of an inducible Cas9 RT-nickase cell line.

### Claim 25 (depends on 1)

The method of claim 1, wherein the determining of the counts of the plurality of different target sequence edits comprises:
receiving a plurality of sequence reads;
for each of the plurality of sequence reads, determining if the sequence read belongs to an aligning set consisting of the sequence reads of the plurality of sequence reads that align to a reference amplicon, the reference amplicon comprising the target sequence;
for each variant sequence of a set of variant sequences, determining a count of the sequence reads of the aligning set that comprise the variant sequence, each variant sequence of the set of variant sequences independently comprising the target sequence modified according to a target sequence edit of the plurality of different target sequence edits; and
determining a count of the sequence reads of the aligning set that do not match any variant sequence of the set of variant sequences, and that differ from the target sequence by no more than a threshold percentage of base pairs.

### Claim 26 (depends on 25)

The method of claim 25, wherein the threshold percentage is no greater than 15%.

### Claim 27 (depends on 1)

The method of claim 1, wherein the computing of the effect of the target sequence edit comprises:
for each target sequence edit of the plurality of different target sequence edits, fitting the counts in the plurality of sets to a log-normal distribution; and
calculating a percent difference between (a) the log-normal distribution for the target sequence edit, and (b) a log-normal distribution derived by fitting counts of the target sequence in the plurality of sets.

### Claim 28 (depends on 1)

The method of claim 1, wherein the target sequence comprises a cis-regulatory element (CRE) operably linked to the target gene.

### Claim 29 (depends on 1)

The method of claim 1, wherein the plurality of different target sequence edits each independently comprise one or more substitutions, insertions, deletions, or a combination thereof, relative to the target sequence.

### Claim 30 (depends on 1)

The method of claim 1, wherein the determining of the count of the plurality of different target sequence edits comprises sequencing a target region of the genomes of the population of cells, the target region comprising the target sequence prior to the introducing of the plurality of different target sequence edits into the population of cells.

### Claim 31 (depends on 1)

The method of claim 1, wherein the plurality of different target sequence edits comprises at least 3 different target sequence edits.

### Claim 32 (depends on 1)

The method of claim 1, wherein the plurality of sets comprises at least 3 sets.

### Claim 33 (depends on 1)

The method of claim 1, wherein the measuring of the parameter comprises using a phenotypic assay.

### Claim 34 (depends on 33)

The method of claim 33, wherein the phenotypic assay comprises a fluorescence-in-situ-hybridization (FISH) assay, a fluorescence assay, an immunofluorescence assay, a growth assay, or a combination thereof.

### Claim 35 (depends on 1)

The method of claim 1, wherein the separating of the population of cells comprises fluorescence activated cell sorting (FACS).

### Claim 36 (depends on 13)

A composition comprising the plurality of template polynucleotides of claim 13.

### Claim 37 (depends on 13)

A population of cells comprising the plurality of template polynucleotides of claim 13.

### Claim 38 (depends on 1)

A cell comprising a genome incorporating a target sequence edit of the plurality of different target sequence edits of claim 1.

### Claim 39 (depends on 38)

The cell of claim 38, wherein the cell is a monocyte or T cell.

### Claim 40 (depends on 13)

A method of treating a subject having a disease dependent on expression of the target gene of claim 13, the method comprising administering to the subject a therapeutically effective amount of the plurality of template polynucleotides of claim 13.

### Claim 41 (depends on 40)

The method of claim 40, wherein the target gene encodes peptidylprolyl isomerase F (PPIF).

### Claim 42 (depends on 41)

The method of claim 41, wherein the disease comprises inflammatory bowel disease.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

A computer product comprising a non-transitory computer readable medium storing a plurality of instructions that, when executed, cause a computer system to perform the method of any one of claims 1-35.

### Claim 44 (depends on 43)

A system comprising:
the computer product of claim 43; and
one or more processors for executing instructions stored on the computer readable medium.
